Postbiotics with pembrolizumab for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding postbiotics (beneficial bacteria byproducts) to the standard immunotherapy drug pembrolizumab can improve your immune system's response against advanced or metastatic head and neck squamous cell carcinoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic head and neck squamous cell carcinoma that cannot be cured with surgery or radiation.
- Your cancer has a protein called PD-L1 (a marker that helps pembrolizumab work).
- You have not had any prior systemic treatment (like chemotherapy or immunotherapy) for your advanced or metastatic cancer.
- You are able to have a tumor biopsy safely.
- You are willing to provide blood, mouth swab, stool, and tumor samples for research.
- You agree to avoid probiotics, yogurt, or foods with added bacteria during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
This trial tests whether pembrolizumab (an immunotherapy) combined with chemotherapy works better as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the oral/throat area. It aims to improve cancer control and help people live longer with fewer side effects than standard care.
This trial tests whether adding lovastatin (a cholesterol-lowering drug) to pembrolizumab (an immunotherapy) works better than pembrolizumab alone for head and neck cancer that has come back or spread. It's for people who haven't had immunotherapy before and aren't already on a statin.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial studies whether pembrolizumab plus chemotherapy (platinum and gemcitabine) can control recurrent or metastatic head and neck squamous cell carcinoma that can’t be cured with local treatments. It may help shrink tumors and slow disease growth in people who haven’t had cancer medicines for this stage before.
Hear when a new Head & Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.